Secondary Antibodies

PrEST Antigen ANKLE2 ankyrin repeat and LEM domain containin

Recombinant protein fragment of Human ANKMY2 with N-terminal His6ABP (ABP = Albumin Binding Protein derived from Streptococcal Protein G) fusion tag. Application Suitable as a blocking agent using corresponding antibodies.

Recombinant protein fragment of Human ANKMY2 with N-terminal His6ABP (ABP = Albumin Binding Protein derived from Streptococcal Protein G) fusion tag. Application Suitable as a blocking agent using corresponding antibodies.

Recombinant protein fragment of Human ANKMY2&nbspwith&nbspN-terminal His 6 ABP (ABP = Albumin Binding Protein derived from Streptococcal Protein G) fusion tag.&nbsp &nbsp&nbsp Application Blocking agent and positive assay control using

Recombinant protein fragment of Human ANKRA2&nbspwith&nbspN-terminal His 6 ABP (ABP = Albumin Binding Protein derived from Streptococcal Protein G) fusion tag.&nbsp &nbsp&nbsp Application Blocking agent and positive assay control using

Recombinant protein fragment of Human ANKRD2 with N-terminal His6ABP (ABP = Albumin Binding Protein derived from Streptococcal Protein G) fusion tag. Application Suitable as a blocking agent using corresponding antibodies.

Recombinant protein fragment of Human ANKRD2 with N-terminal His6ABP (ABP = Albumin Binding Protein derived from Streptococcal Protein G) fusion tag. Application Suitable as a blocking agent using corresponding antibodies.

Recombinant protein fragment of Human ANO2 with&nbspN-terminal His6ABP (ABP = Albumin Binding Protein derived from Streptococcal Protein G) fusion tag Application Blocking agent and positive assay control using corresponding antibodies. Physical

PrEST Antigen ANXA11 annexin A11, 100ul UN 1687 6.1 PG2

PrEST Antigen ANXA13 annexin A13, 100ul UN 1687 6.1 PG2

PrEST Antigen ANXA13 annexin A13, 100ul UN 1687 6.1 PG2

Recombinant protein fragment of Human ANXA2 with&nbspN-terminal His6ABP (ABP = Albumin Binding Protein derived from Streptococcal Protein G) fusion tag.&nbsp &nbsp&nbsp Application Blocking agent and positive assay control using corresponding